For: | Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v24/i17/1825.htm |
Number | Citing Articles |
1 |
Anastasiya Kostyusheva, Dmitry Kostyushev, Sergey Brezgin, Elena Volchkova, Vladimir Chulanov. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes 2018; 9(10): 483 doi: 10.3390/genes9100483
|
2 |
Urbano Sbarigia, Furaha Kariburyo, Janvi Sah, Jamie Colasurdo, Lin Xie, Eva G. Katz, Shirley Sylvester. Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population. Advances in Therapy 2020; 37(3): 1156 doi: 10.1007/s12325-020-01240-1
|
3 |
Margarita Papatheodoridi, Tung‐Hung Su, Emilia Hadziyannis, Chun‐Hsun Liao, Αfroditi Orfanidou, Hung‐Chi Yang, Kalliopi Zachou, Chun‐Jen Liu, Anastasia Kourikou, Nikolaos Gatselis, Spilios Manolakopoulos, George Dalekos, Jia‐Horng Kao, Stephanos Hadziyannis, George V. Papatheodoridis. Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study. Liver International 2022; 42(3): 541 doi: 10.1111/liv.15128
|
4 |
İlknur Esen Yıldız, İlkay Bahçeci, Tuğba Ilgar, Mehmet Beyazal, Uğur Kostakoğlu, Ayşe Ertürk. Is Liver Biopsy Necessary in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase Level?. Viral Hepatitis Journal 2022; 28(1): 1 doi: 10.4274/vhd.galenos.2021.2021-7-1
|
5 |
Yafei Guo, Lingan Wang. Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”. Canadian Journal of Gastroenterology and Hepatology 2019; 2019: 1 doi: 10.1155/2019/4927083
|
6 |
Ching-Lung Lai, Danny Ka-Ho Wong, Gerald Tsz-Yau Wong, Wai-Kay Seto, James Fung, Man-Fung Yuen. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. JHEP Reports 2020; 2(3): 100112 doi: 10.1016/j.jhepr.2020.100112
|
7 |
Henar Calvo Sánchez, Julia Peña-Asensio, Juan Ramón Larrubia Marfil. Current challenges in the functional cure of HBe-antigen negative chronic hepatitis B. Revista Española de Enfermedades Digestivas 2022; 114 doi: 10.17235/reed.2022.9052/2022
|
8 |
Mingming Zhang, Han Chen, Huan Liu, Hong Tang. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomarker Research 2024; 12(1) doi: 10.1186/s40364-024-00611-y
|
9 |
Mala K. Maini, Alice R. Burton. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nature Reviews Gastroenterology & Hepatology 2019; 16(11): 662 doi: 10.1038/s41575-019-0196-9
|
10 |
Jirayu Kammarabutr, Panupong Mahalapbutr, Hisashi Okumura, Peter Wolschann, Thanyada Rungrotmongkol. Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. Journal of Biomolecular Structure and Dynamics 2021; 39(7): 2502 doi: 10.1080/07391102.2020.1751715
|